

Electronic Acknowledgement Receipt

EFS ID:	4847040
Application Number:	10551350
International Application Number:	
Confirmation Number:	3238
Title of Invention:	Modified polynucleotides for use in ma interference
First Named Inventor/Applicant Name:	Devin Leake
Customer Number:	22913
Filer:	John C. Stringham/Tyler Eller
Filer Authorized By:	John C. Stringham
Attorney Docket Number:	16542.16.1a.3
Receipt Date:	24-FEB-2009
Filing Date:	19-OCT-2006
Time Stamp:	14:30:35
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	NPL_Newly_Released_SureSilencing_Mouse.pdf	387744 08110509b7ac7f9f7b5c0f1bc229d617f0beea11f	no	7

Warnings:

Information:

2	NPL Documents	NPL_Newly_Released_SureSilencing_Human.pdf	204650 7115db45913ab7a08e01aede15254e095f88615	no	4
Warnings:					
Information:					
3	NPL Documents	NPL_Transfection_Reagent_Selector_Kit_Handbook.pdf	1916392 28ee6401005a63bc3f542619955430e9af150903	no	32
Warnings:					
Information:					
4	NPL Documents	NPL_The_Rest_is_Silence.pdf	1374997 141a71d8d23d87f3dce9d247388b424e5f08c834	no	14
Warnings:					
Information:					
5	NPL Documents	NPL_RNAi_Microarray_Analysis_Cultured_Mammalian.pdf	895447 c9cc13d6d2568b27d595eaf5b0d64e80e5b2601	no	8
Warnings:					
Information:					
6	NPL Documents	NPL_High-throughput_Gene_Silencing_Using_Cell_Arrays.pdf	597304 6de1995d753c73ba9f4fa26a526a5f05e5f3a8f8b1	no	8
Warnings:					
Information:					
7	NPL Documents	NPL_RNA_Interference_Microarrays_High-Throughput.pdf	590833 b2987186d9d75e940cc221b5548bd511e07c3b00	no	5
Warnings:					
Information:					
8	NPL Documents	NPL_High-Throughput_Selection_Effective_RNAi.pdf	806662 b9444cc93facc0bd163d890b3a062d73f976ba6	no	8
Warnings:					
Information:					
9	NPL Documents	NPL_Applications_Transferred_Cell_Microarrays.pdf	523380 e3ed2a0e090901e46027f943d8ff7d8000902677d6	no	6
Warnings:					
Information:					
10	NPL Documents	NPL_Role_Atelo collagen-Based_Cell_Transfection.pdf	723975 e9780751d87a90663b1e0b799f0eab109dc0d88	no	8
Warnings:					
Information:					

11	NPL Documents	ISR_PCT_US05_42407.pdf	62901 08123a4d49c4b66c3abdc1f8f5c48f24d9c5d	no	1
Warnings:					
Information:					
12	NPL Documents	Prelim_Report_Patentability_U S05_42407.pdf	50990 2711b3a6d6c32ae62786273becfca70788a4d78	no	1
Warnings:					
Information:					
13	NPL Documents	Written_Opinion_PCT_US05_4 2407.pdf	242006 ef8fc1ef579c4fc4555d28035a7454688019278e	no	6
Warnings:					
Information:					
14	NPL Documents	ISR_PCT_US05_42403.pdf	95399 82ad76c315d45cbb6d4577b96c750746912c5172	no	3
Warnings:					
Information:					
15	NPL Documents	Prelim_Report_Patentability_U S05_42403.pdf	51025 8df2e6cd6c209814548f93d1261259c1ee574d7	no	1
Warnings:					
Information:					
16	NPL Documents	Written_Opinion_PCT_US05_4 2403.pdf	297187 46c341e80e023876ea772c24c25c4b48c2fdab38	no	6
Warnings:					
Information:					
17	NPL Documents	ISR_PCT_US05_42385.pdf	79025 b3c468bc329ac1e8a1546208cc21fcaadac605d	no	2
Warnings:					
Information:					
18	NPL Documents	Prelim_Report_Patentability_U S05_42385.pdf	51096 c3ub3079c661ca12d8adfd13ee3bd4d454b4d4d	no	1
Warnings:					
Information:					
19	NPL Documents	Written_Opinion_PCT_US05_4 2385.pdf	256588 880da0a574610ac16d294f8d188f4c49ceef3f	no	6
Warnings:					
Information:					

20	NPL Documents	ISR_PCT_US2005_042404.pdf	64112 e5d60e418dc0e48024f78ace1e0d16d101e0d0	no	1
Warnings:					
Information:					
21	NPL Documents	Prelim_Report_Patentability_PCT_US2005_042404.pdf	50621 88a105c4b6f0ac12ed02d344e48de42ed701813f	no	1
Warnings:					
Information:					
22	NPL Documents	Written_Opinion_PCT_US2005_042404.pdf	284779 94dfe04d497abc039661061d86135a2c4b3d7286d	no	8
Warnings:					
Information:					
23	NPL Documents	NPL_Tolerance_For_Mutations_Chemical_Modifications.PDF	553185 f802d0e5143c110d02be1225f7d73e9ca4407	no	7
Warnings:					
Information:					
24	NPL Documents	NPL_Functional_Anatomy_dsRNA_Trigger.PDF	928870 1103c7ab402a04c52f8b14f9f81bb64053e4081	no	11
Warnings:					
Information:					
25	NPL Documents	NPL_RNA_Interference_Mediated_by_21-21_nucleotide_RNA_PDF	1548408 c78ac5af1338c72f8cc00b38b3665258d9409e	no	14
Warnings:					
Information:					
26	NPL Documents	NPL_Cholesteryl_Conjugated_Oligonucleotides.pdf	383061 cc864f0c6dbaf12e6cfc534778ec2365b1fa515	no	4
Warnings:					
Information:					
27	NPL Documents	NPL_Antisense_2-O-Alkyl_Oligoribonucleotides.pdf	916648 791105c1a023a5baec6389f21162a109191c14e4	no	9
Warnings:					
Information:					
28	NPL Documents	NPL_siRNA_Function_in_RNA_Chemical_Modification.pdf	1649364 5a3abafaf0f5c599a0ff1fba140d1888e7e5c8eb	no	16
Warnings:					
Information:					

29	NPL Documents	NPL_Enzymatic_Synthesis_2-Modified_Nucleic_Acids.pdf	1523392 548880db5606a529f6ab5704edf93ee7917e5b9e4	no	10
Warnings:					
Information:					
30	NPL Documents	NPL_Structural_Variations_Stabilising_Modifications.pdf	1098547 2f82ed7ad73e126aa2980c5f12e0592d17a52676	no	13
Warnings:					
Information:					
31	NPL Documents	NPL_Comparison_Different_Antisense_Strategies.pdf	952997 5f5b8cc2f8947d86e533aac1ab6b79d7967cddaf	no	10
Warnings:					
Information:					
32	NPL Documents	NPL_Similar_Behavior_Single-Strand_Double_Strand.pdf	686566 899f9bd2f6600ca04bb1c86a8f5ecaa0f654a5	no	8
Warnings:					
Information:					
33	NPL Documents	NPL_Target_Specific_Arrest_mRNA_Translation.pdf	1013593 26f9ba32ab563a8ac8ef6f994a81201aa53a5846	no	9
Warnings:					
Information:					
34	NPL Documents	NPL_RNase_H_Responsible_Non-Specific_Inhibition.pdf	850115 6292803ce7c747d666dec40b33117a80749cd6a7e	no	8
Warnings:					
Information:					
35	NPL Documents	NPL_Optimizing_Delivery_Systems_Chimeric_RNA.pdf	566212 5495408bf5caca30095c0db1ec7bb6a8bd255aff	no	7
Warnings:					
Information:					
36	NPL Documents	NPL_Advantages_2'-O-Methyl_Oligoribonucleotide.pdf	552836 9c2508338b108daf7642e4c9465676b2aac405e	no	7
Warnings:					
Information:					
37	NPL Documents	NPL_Evaluation_2-Modified_Oligonucleotides.pdf	1142986 46de4be37c51810195a08353c2cb73d87c2248	no	10
Warnings:					
Information:					

38	NPL Documents	NPL_ATP_Requirements_Small _Interfering_RNA.pdf	1257593 e29c500f3ed40615a181d7c33bab0f39ae5 0a37c	no	14
Warnings:					
Information:					
39	NPL Documents	NPL_Use_Modified_Primer_Eli minate_Cycle.pdf	927747 6d1e5e7387ab45ce480392536245e42b7e7 a0d3e	no	8
Warnings:					
Information:					
40	NPL Documents	NPL_Studies_Interactions_Bet ween_E-Coli.pdf	848228 c0b9d801a68479a15d42e7f9c0eb560af ed93	no	11
Warnings:					
Information:					
41	NPL Documents	NPL_Sequence_Chemical_Str uctural_Variation.pdf	2074656 7979acd8b6e141d0dd3e4538e1d62011 0303d6	no	24
Warnings:					
Information:					
42	NPL Documents	NPL_Functional_Anatomy_siR NA_Mediating_Efficient.pdf	1081464 074b2b78abac7d49d797ecb1677494385 11ac0	no	12
Warnings:					
Information:					
43	NPL Documents	NPL_Expression_Profiling_Reve als_Off-Target.pdf	297517 d4ab4086c910191a199a03d6b7fb3ac27c 5327e	no	4
Warnings:					
Information:					
44	NPL Documents	NPL_Stabilizing_Effects_RNA_2 -Substituent.pdf	838021 2d854077d68b0d6820bc5f8b290849a0b 5c373	no	7
Warnings:					
Information:					
45	NPL Documents	NPL_Dharamacon_Merck_Rose tta_Collaborate_Press_Release. pdf	114012 88c0a1fa7f6120d1bade5c5e4513e14e 153	no	1
Warnings:					
Information:					
46	NPL Documents	NPL_Rosetta_siRNA_Experime nts_Performed_2007.pdf	831443 9063995a8b3e200711a736663779c4206 b122	no	11
Warnings:					
Information:					

47	NPL Documents	NPL_Cholesterol_Connection_in_RNAi.pdf	235745 44f3a6dace8f15b136e497e7bda243c7ab db21	no	2
Warnings:					
Information:					
48	NPL Documents	NPL_Therapeutic_Silencing_Endogenous_Gene.pdf	582300 1591670253eaa3d15e0b867a80097803e12 6a3ee	no	6
Warnings:					
Information:					
49	NPL Documents	NPL_Synthetic_dsRNA_Dicer_Substrates_Enhance.pdf	561399 b4c9b97b1474f4ef7c22b7eefc7d4e6c3 302.	no	5
Warnings:					
Information:					
50	NPL Documents	NPL_Short_Hairpin_RNAs_Induce_Sequence.pdf	831189 430ac6b0b0c271a1b1d4dbaf67c5726f6f 35ade	no	11
Warnings:					
Information:					
51	NPL Documents	NPL_Human_Dicer_Preferentially_Cleaves_dsRNAs.pdf	1088342 338c56d6e54b9946a50b3c6c6b477f55 96af	no	11
Warnings:					
Information:					
52	NPL Documents	NPL_Enhancement_RNAi_Activity_by_Improved.pdf	477650 8bb7e452682c094a6c342ab051a347130 880	no	6
Warnings:					
Information:					
53	NPL Documents	NPL_Structural_Basis_Overhang-Specific_Small.pdf	543904 18c70e4ac227f65d6c35dcb62d2d2e986c2 e3b61	no	5
Warnings:					
Information:					
54	NPL Documents	NPL_Synthetic_shRNAs_Potential_RNAi_Triggers.pdf	528314 6c56b6c703e6b0d8a4d94db80a652b411 792cc	no	5
Warnings:					
Information:					
55	NPL Documents	NPL_Both_Natural_Designed_Micro_RNAs.pdf	569759 d8f5078c3c325e7801ce456f59acc9b1f eef	no	7
Warnings:					
Information:					

56	NPL Documents	NPL_Positional_Effects_Short_I nterfering_RNAs.pdf	1052026 5c95b07b4d6d1b84b-901c93b6d0121c7b 9b0	no	11
Warnings:					
Information:					
57	NPL Documents	ISR_PCT_US05_011008.pdf	148619 467ba7bc282c8422c6f8b2ad81ca2988f7c1c 1a1a	no	5
Warnings:					
Information:					
58	NPL Documents	Written_Opinion_PCT_US05_0 11008.pdf	225882 b84c82baa62bc79a55a163d86144157f1c2 95c386	no	6
Warnings:					
Information:					
59	NPL Documents	ISR_PCT_US05_003365.pdf	234795 714b0b0c2ed6c9912f81713ced6d6d72 9c1b	no	7
Warnings:					
Information:					
60	NPL Documents	Written_Opinion_PCT_US05_0 03365.pdf	374299 e6d1a082e2c01a648c54e23e7a94b851c5 3a6f9	no	10
Warnings:					
Information:					
Total Files Size (in bytes):			39698797		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.